US · Healthcare · Biotechnology
EPS came in at -0.45 against a street estimate of -0.38 — a miss of 18.4%.
Analysts rate Monte Rosa Therapeutics Inc a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $30.67.
| Fund | Stake |
|---|---|
| NEA Management Company, LLC | 9.11% |
| T. Rowe Price Associates, Inc. | 7.95% |
| BlackRock Inc | 6.67% |
| TCG Crossover Management, LLC | 5.47% |
| Bvf Inc | 5.28% |
| Baker Bros Advisors LP | 5.14% |
| Suvretta Capital Management, LLC | 5.00% |
| Vestal Point Capital LP | 4.27% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-11 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-29 |
| Annual report FY2025 | 2026-03-17 |
| Results announced · Q1 2026 | 2026-03-17 |
| Board / officer change · Q1 2026 | 2026-02-10 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Monte Rosa Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.